Principal Investigator
Gary Kleiner
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230074
Clinical Trial Summary
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy (VITESSE)
Phase
Phase III
Funding Agency/Sponsor
Intramural
Disease
Other